Fineline Cube

Follow:
14691 Articles
AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances
Others

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

CompanyDeals

GeneScience Acquires Global Rights to Megestrol Acetate Oral Suspension from TWi Pharmaceuticals – $100M Deal Transforms Distributor into MAH for Cachexia Therapy

ApicHope's Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market
CompanyDrug

ApicHope’s Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China's OTC Analgesic Market
Others

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China’s OTC Analgesic Market

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China's RMB 7.8 Billion Heart Failure Market
CompanyDrug

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China’s RMB 7.8 Billion Heart Failure Market

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio
CompanyDrug

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism
CompanyDrug

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Pfizer's TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk
CompanyDrug

Pfizer’s TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Roche's Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing
CompanyDrug

Roche’s Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent
CompanyDeals

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio
CompanyDeals

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio